T63229
|
|
|
|
ITK inhibitor 6 是选择性的、有效的 ITK 抑制剂,能够作用于 ITK (IC50: 4 nM)、BTK (IC50: 133 nM)、JAK3 (IC50: 320 nM)、EGFR (IC50: 2360 nM)、LCK (IC50: 155 nM)。ITK inhibitor 6 对 PLCγ1 和 ERK1/2 的磷酸化具有抑制作用,表现出抗增殖效果。 |
T39129
|
|
|
|
BMS-986143 是一种口服有效的、可逆的BTK 抑制剂,IC50为 0.26 nM,具有自身免疫性疾病的研究潜力。BMS-986143 还抑制 TEC、BLK、BMX、TXK FGR、YES1、ITK,IC50分别为 3 nM、5 nM、7 nM、10 nM、15 nM、19 nM、21 nM。 |
T73942
|
|
|
|
(Rac)-IBT6A hydrochloride 是 IBT6A hydrochloride 的消旋体。IBT6A 是 Ibrutinib 的一种杂质。IBT6A 可用于合成 IBT6A-Ibrutinib 二聚体和 IBT6A 加合物。Ibrutinib 是一种不可逆的选择性 Btk 抑制剂,IC50为 0.5 nM。 |
T70446
|
|
|
|
Abivertinib, also known as AC0010 and Avitinib, is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor that demonstrated clinical efficacy and manageable adverse events (AEs). Abivertinib inhibits cell proliferation, reduces colony-forming capacity, and induces apoptosis and cell cycle arrest in AML cells, especially those harboring FLT3-ITD mutations. Abivertinib was also found to be more sensitive than ibrutinib in treating AML. Abivertinib may be a promising novel agent for AML, with potential for combination treatment with HHT. |
T82714
|
|
|
|
Civorebrutinib (WS-413)是一种Bruton's tyrosine kinase (BTK) 抑制剂,展现出了抗肿瘤活性。 |
T36421
|
|
|
|
The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list of targets. Stability data is not available for the compounds as supplied in the screening library. |
T10802
|
|
|
EGFR
|
CHMFL-EGFR-202 是一种有效、不可逆的表皮生长因子受体 (EGFR) 突变型激酶抑制剂, 对耐药突变型 EGFR T790M 和 WT EGFR 激酶作用的 IC50 分别为 5.3 nM 和 8.3 nM。 |
T83911
|
|
|
|
CYY292是一种针对PDGFRα、PDGFRβ、FGFR1、-2和-3的抑制剂(IC50分别为5.35、4.6、28、28和78 nM)。该化合物对这些激酶的选择性高于FGFR4(IC50 > 1,000 nM),但也能抑制c-Kit、VEGFR2、VEGFR1和胰岛素样生长因子1受体(IGF-1R;IC50分别为67、33、36和75 nM),以及EGFR、布鲁顿酪氨酸激酶(BTK)、细胞周期依赖性激酶4(Cdk4)/cyclin D3和MET(IC50分别为128、198、214和396 nM)。CYY292抑制MG-63、U2OS、MNNG/HOS和Saos-2骨肉瘤细胞的增殖(IC50分别为0.84、0.76、1.36和0.72 µM)。在0.3和0.5 µM的浓度下,它抑制U87MG和LN-229胶质母细胞瘤细胞的迁移和侵袭。CYY292(30 mg/kg)在U87MG原位小鼠异种移植模型中降低肿瘤体积并增加生存率。 |
T15607
|
|
|
Others
|
JAK3-IN-1 is a selective and orally active JAK3 inhibitor (IC50: 4.8 nM). JAK3-IN-1 displays over 180-fold more selective for JAK3 than JAK1 (IC50: 896 nM) and JAK2 (IC50: 1050 nM). |
T16578
|
|
|
Others
|
PRN694 shows extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo. PRN694 is an irreversible, highly selective, and effective covalent interleukin-2-inducible T-cell kinase (ITK) and resting ly |